Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02373332 · ClinicalTrials.gov registry record
Fatty Acid Regulation of Platelet Function in Diabetes
A clinical trial, sponsored by University of Michigan.
- Completed
- Registry status
- 90
- Enrollment target
NCT02373332: Completed study, sponsored by University of Michigan.
NCT02373332 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02373332 has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 90 participants
- Enrollment target
Study Summary
This study investigates the potential protective effects of altering fatty acid in the platelet as a method for prevention of platelet activation and thrombosis in type 2 diabetes mellitus. Fatty acids (omega-3 and omega-6) and their oxidized lipids will be evaluated for protection from agonist-mediated platelet activation in platelets from type 2 diabetics and healthy controls.
Primary Outcome
following blood draw, the ability of fatty acids or their oxylipins to inhibit platelet activation will be assessed.
Interventions
- OTHER omega-3 and -6 fatty acids and their 12-LOX oxylipins
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2013-08 |
| Est. Completion | 2019-05-21 |
What the finished NCT02373332 record still lists
NCT02373332 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which omega-3 and -6 fatty acids and their 12-LOX oxylipins is the first listed.
NCT02373332 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02373332 about?
NCT02373332 is a clinical study titled "Fatty Acid Regulation of Platelet Function in Diabetes". This study investigates the potential protective effects of altering fatty acid in the platelet as a method for prevention of platelet activation and thrombosis in type 2 diabetes mellitus. Fatty acids (omega-3 and omega-6) and their oxidized lipids will be evaluated for protection from agonist-medi...
What is the current status of trial NCT02373332?
This trial is currently completed. The enrollment target is 90 participants. The study started on 2013-08. Estimated completion is 2019-05-21.
What interventions are being tested in trial NCT02373332?
The interventions under investigation include: omega-3 and -6 fatty acids and their 12-LOX oxylipins (OTHER).
Who is sponsoring clinical trial NCT02373332?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia